Cholera as a model for research on mucosal immunity and development of oral vaccines.
During the past year, the extensive investigational use of a recently developed oral vaccine against cholera has led to significant advances in our understanding of both immunity to cholera and related diarrhoeal diseases, and the mucosal immune response in general after oral immunization. The oral cholera vaccine has been shown to protect, through its cholera toxin B subunit component, against travellers' diarrhoea caused by enterotoxigenic Escherichia coli. The elaboration of sensitive new techniques has allowed detailed clonal analyses of the activation of specific B and T cells and immunologic memory in intestinal mucosa in humans after oral cholera vaccination. These techniques have also been used to demonstrate a transient appearance after immunization of specific gut-derived IgA antibody-producing cells in the circulation and also, a few days later, in a distant mucosal tissue such as the salivary glands.
Holmgren
J
J
Department of Medical Microbiology and Immunology, University of Göteborg, Sweden.
Czerkinsky
C
C
D000284:Administration, Oral; D000942:Antigens, Bacterial / Q000096:biosynthesis; D002771:Cholera / Q000276:immunology* / Q000517:prevention & control; D022121:Cholera Vaccines / Q000008:administration & dosage / Q000276:immunology*; D003967:Diarrhea / Q000517:prevention & control; D004311:Double-Blind Method; D004927:Escherichia coli Infections / Q000517:prevention & control; D006801:Humans; D007413:Intestinal Mucosa / Q000276:immunology; D012485:Salmonella typhi / Q000276:immunology; D014734:Vibrio cholerae / Q000276:immunology
D000942:Antigens, Bacterial; D022121:Cholera Vaccines